STAAR Surgical Co

News & Events zu STAAR Surgical Co (STAA)

$23.110

-0.402 (-1.74%)Zum Schluss

STAA-News

STAA-Events

9/2 16:30

Staar Surgical Appoints Ben Park as Chief Technology Officer

Staar Surgical announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer. "Evolving STAAR from a single-product focus into a multi-product platform is central to our strategy - and requires the right leader," said Foust. "Ben Park is that leader. We have been delivering on revenue growth and profitability, and now it's time to match that momentum with equal urgency on innovation. With our R&D and Advanced Research teams preparing for first-in-human studies of our next-generation products, the moment to accelerate is now. Ben's track record of success in building and commercializing breakthrough medical device platforms makes him the ideal person to advance our innovation roadmap and unlock the full potential of our proprietary Collamer technology." Dr. Park joins STAAR from Align Technology, Inc., where he served as Head of Emerging Technology since 2018. In that role, Dr. Park built and led a global multidisciplinary team - spanning biomedical engineering, hardware, embedded systems, and software across the U.S. and APAC - to define next generation product platforms and address unmet clinical needs, from concept through to market launch.

8/12 16:30

STAAR Reports Q2 Revenue of $93.5M, Beating Expectations

Reports Q2 revenue $93.5M, consensus $90.6M. The company states: "Nearly six months ago, we set a clear agenda: Revenue Growth, Profit Expansion, and Innovation Acceleration. In the first half of this year, we delivered on all three. In the second quarter, we grew revenue, gross margin and net income - versus both the year-ago quarter and the first quarter. Demand for ICL procedures is strong in our key markets. In our largest market, China, representing over 50% of revenue, our sales benefited from gains in market share, driven by both volume growth and ASP expansion, which were supported by an improving product mix following the successful launch of EVO+ in the first quarter. Importantly, we saw no evidence of excess ICL inventory at our distributors or hospitals in China. Other key markets, including Japan and Korea, continue to contribute meaningfully to revenue, while the Americas and EMEA (excluding the Middle East) delivered double-digit growth. The current demand dynamics should continue throughout the remainder of the year. As part of our focus on achieving our revenue growth goals, we are concurrently focused on continuously improving our production and supply chain efficiency to support our customers, partners and the patients we serve. We increased investments in ERP, supply chain and production efficiency during the second quarter, yet we still delivered the highest first half adjusted EBITDA results in STAAR's history. These strategic investments are foundational to improving our operating leverage and driving a stronger incremental revenue-to-adjusted EBITDA conversion ratio. The math is straightforward: with a largely fixed cost base and the right infrastructure in place, margin expansion will naturally follow revenue growth."

8/4 17:00

STAAR Surgical Appoints Warren Foust as New CEO

STAAR Surgical Company announced that following an extensive global search, its Board of Directors has appointed Warren Foust as President and CEO and a new member of the Board of Directors. Mr. Foust joined STAAR in April 2023 and has served as President and COO since March 2025 and as Interim Co-CEO, President & COO since February 2026. Deborah Andrews, who has served since February as Interim Co-CEO alongside Mr. Foust, will serve as Executive Vice President. She will also continue to serve as CFO. The Company remains focused on helping its customers to provide visual freedom for patients while delivering on its three principal strategy pillars: revenue growth, profit expansion, and innovation acceleration.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten